MAPK7 and neoplasm: Molecular validation revealed a marked reduction of FGF17 protein levels in tumor samples from the shFGF17 group (p < 0.001), accompanied by concurrent suppression of its receptor FGFR4 and downstream p-MEK5 and p-ERK5 (Thr218/Tyr220) (p < 0.05).